Effects and Safety of OPK-88003 Dose Escalation in Type 2 Diabetes Subjects

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 113 participants.

Also called NCT03406377

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 113 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03406377
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03406377. Randomized; triple masking; primary purpose treatment. Start 2018-04-02 (actual); primary completion 2019-03-08 (actual). Results posted on 2021-06-15.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effects and Safety of OPK-88003 Dose Escalation in Type 2 Diabetes Subjects
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
OPK-88003
Intervention (Drug)
Placebo
Lead sponsor
OPKO Health, Inc. (class: industry)

Record details

Record id
cardio:ct-nct03406377
Content hash
2c215ed59691fb122f5036d6dda17d98fd052c3ce7d6517af9c9b8a17ae8150a